HRP20130538T1 - Therapeutic uses of quinazolinedione derivatives - Google Patents

Therapeutic uses of quinazolinedione derivatives

Info

Publication number
HRP20130538T1
HRP20130538T1 HRP20130538AT HRP20130538T HRP20130538T1 HR P20130538 T1 HRP20130538 T1 HR P20130538T1 HR P20130538A T HRP20130538A T HR P20130538AT HR P20130538 T HRP20130538 T HR P20130538T HR P20130538 T1 HRP20130538 T1 HR P20130538T1
Authority
HR
Croatia
Prior art keywords
therapeutic uses
quinazolinedione derivatives
quinazolinedione
derivatives
therapeutic
Prior art date
Application number
HRP20130538AT
Other languages
English (en)
Inventor
Gilbert Marciniak
Jean-François Nave
Fabrice Viviani
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20130538T1 publication Critical patent/HRP20130538T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HRP20130538AT 2009-03-27 2013-06-13 Therapeutic uses of quinazolinedione derivatives HRP20130538T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0901460A FR2943673B1 (fr) 2009-03-27 2009-03-27 Applications therapeutiques de derives de quinazolinedione
PCT/FR2010/050549 WO2010109148A1 (fr) 2009-03-27 2010-03-25 Applications therapeutiques de derives de quinazolinedione

Publications (1)

Publication Number Publication Date
HRP20130538T1 true HRP20130538T1 (en) 2013-07-31

Family

ID=41203772

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130538AT HRP20130538T1 (en) 2009-03-27 2013-06-13 Therapeutic uses of quinazolinedione derivatives

Country Status (31)

Country Link
US (1) US8748441B2 (hr)
EP (1) EP2411009B8 (hr)
JP (1) JP5654559B2 (hr)
KR (1) KR101686263B1 (hr)
CN (1) CN102448461B (hr)
AR (1) AR075955A1 (hr)
AU (1) AU2010227359B2 (hr)
BR (1) BRPI1014688A2 (hr)
CA (1) CA2756645A1 (hr)
CL (1) CL2011002382A1 (hr)
CO (1) CO6430429A2 (hr)
CY (1) CY1114400T1 (hr)
DK (1) DK2411009T3 (hr)
EA (1) EA023670B1 (hr)
ES (1) ES2411880T3 (hr)
FR (1) FR2943673B1 (hr)
HK (1) HK1164721A1 (hr)
HR (1) HRP20130538T1 (hr)
IL (1) IL215368A0 (hr)
MA (1) MA33218B1 (hr)
MX (1) MX2011010150A (hr)
NZ (1) NZ595405A (hr)
PL (1) PL2411009T3 (hr)
PT (1) PT2411009E (hr)
SG (1) SG174931A1 (hr)
SI (1) SI2411009T1 (hr)
SM (1) SMT201300067B (hr)
TW (1) TWI471313B (hr)
UY (1) UY32526A (hr)
WO (1) WO2010109148A1 (hr)
ZA (1) ZA201107009B (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
JP2014504271A (ja) * 2010-11-08 2014-02-20 オメロス コーポレーション Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
RS58381B1 (sr) * 2012-05-07 2019-04-30 Omeros Corp Lečenje zavisnosti i poremećaja kontrole impulsa upotrebom pde7 inhibitora
WO2013177349A2 (en) * 2012-05-25 2013-11-28 Glaxosmithkline Llc Quinazolinediones as tankyrase inhibitors
WO2013184806A1 (en) 2012-06-05 2013-12-12 University Of Kansas Inhibitors of respiratory syncytial virus
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
AU2020284606B2 (en) * 2019-05-31 2023-01-19 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2715884C1 (ru) * 2019-06-24 2020-03-04 федеральное государственное автономное образовательное учреждение высшего образования "Северо-Кавказский федеральный университет" 2-бензилпроизводное 4-(3Н)хиназолинона, обладающее анальгезирующим, противопаркинсоническим, антигипоксантным, транквилизирующим действием
KR102685058B1 (ko) * 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
RU2758333C1 (ru) * 2021-03-22 2021-10-28 федеральное государственное автономное образовательное учреждение высшего образования "Северо-Кавказский федеральный университет" Диметоксибензилсульфопроизводное хиназолин-4(3Н)-она, обладающее анальгезирующей, противопаркинсонической, анксиолитической, психостимулирующей активностью
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX7829A (es) * 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
EP0825993A1 (en) * 1995-05-19 1998-03-04 Chiroscience Limited Xanthines and their therapeutic use
JP2002308774A (ja) * 2001-04-12 2002-10-23 Nippon Zoki Pharmaceut Co Ltd Ｉｖ型ホスホジエステラーゼ選択的阻害剤
EP1348701A1 (en) * 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
CN1980913B (zh) * 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.

Also Published As

Publication number Publication date
NZ595405A (en) 2013-03-28
PL2411009T3 (pl) 2013-09-30
TWI471313B (zh) 2015-02-01
AR075955A1 (es) 2011-05-11
SG174931A1 (en) 2011-11-28
FR2943673A1 (fr) 2010-10-01
BRPI1014688A2 (pt) 2016-04-12
PT2411009E (pt) 2013-05-27
CL2011002382A1 (es) 2012-02-17
MX2011010150A (es) 2011-12-14
CY1114400T1 (el) 2016-08-31
UY32526A (es) 2010-10-29
AU2010227359B2 (en) 2016-08-04
MA33218B1 (fr) 2012-04-02
CN102448461A (zh) 2012-05-09
ES2411880T3 (es) 2013-07-09
HK1164721A1 (en) 2012-09-28
KR20120003904A (ko) 2012-01-11
ZA201107009B (en) 2012-11-28
TW201038539A (en) 2010-11-01
CA2756645A1 (fr) 2010-09-30
DK2411009T3 (da) 2013-06-24
EP2411009A1 (fr) 2012-02-01
EP2411009B8 (fr) 2013-06-26
WO2010109148A1 (fr) 2010-09-30
IL215368A0 (en) 2011-12-29
EA201171172A1 (ru) 2012-04-30
JP2012521974A (ja) 2012-09-20
AU2010227359A1 (en) 2011-10-20
EA023670B1 (ru) 2016-06-30
SMT201300067B (it) 2013-09-06
JP5654559B2 (ja) 2015-01-14
US20120058987A1 (en) 2012-03-08
SI2411009T1 (sl) 2013-07-31
FR2943673B1 (fr) 2013-03-29
EP2411009B1 (fr) 2013-03-20
CN102448461B (zh) 2014-08-06
KR101686263B1 (ko) 2016-12-13
US8748441B2 (en) 2014-06-10
CO6430429A2 (es) 2012-04-30

Similar Documents

Publication Publication Date Title
HRP20130538T1 (en) Therapeutic uses of quinazolinedione derivatives
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
PT2482812T (pt) Composições farmacêuticas compreendendo bi-1356 e metformina
ZA201200054B (en) Therapeutic compounds and compositions
HK1173654A1 (zh) 治療化合物及相關的使用方法
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
GB0908193D0 (en) Treatment of disease state
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
IL206491A0 (en) Treatment of produce
PL2433637T3 (pl) Zastosowanie pochodnych kwinazoliny w chorobach neurodegeneracyjnych
ZA201107363B (en) Quinazolinedione derivatives,preparation thereof and various therapeutic uses thereof
EP2490541A4 (en) 2-SUBSTITUTED ETHYL HYLTHIAZONE DERIVATIVES AND THEIR USE
GB201211237D0 (en) CDK5 inhibitors and therapeutic uses thereof
IL219872A0 (en) Quinazoline derivatives
HK1131039A1 (en) Pharmaceutical use of sophoricoside
ZA201205056B (en) Therapeutic use of protein-polymer conjugates
HU0900647D0 (en) Salts of 7-nitroindoline derivatives and use thereof
GB0821710D0 (en) Derivatives of dihydroindolone
GB0922098D0 (en) Therapeutic use
GB0906047D0 (en) Novel salts of nalmefene and their therapeutic use
GB0913300D0 (en) Therapeutic compounds and their use
AU2009902677A0 (en) Novel Therapeutic Uses of SLIRP